Cwm, LLC Bei Gene, Ltd. Transaction History

Cwm, LLC

$23.3 Billion
Q3 2024

A detailed history of Cwm, LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Cwm, LLC holds 86 shares of BGNE stock, worth $15,399. This represents 0.0% of its overall portfolio holdings.

Number of Shares

Previous 88 2.27%

Holding current value

$15,399

Previous $13,000 46.15%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 08, 2024	SELL	$143.93 - $224.51 $287 - $449	-2 Reduced 2.27%	86 $19,000
Q2 2024 Jul 09, 2024	SELL	$129.52 - $174.32 $1,554 - $2,091	-12 Reduced 12.0%	88 $13,000
Q1 2024 Apr 05, 2024	BUY	$141.8 - $181.47 $4,963 - $6,351	35 Added 53.85%	100 $16,000
Q4 2023 Feb 01, 2024	SELL	$158.67 - $201.58 $4,442 - $5,644	-28 Reduced 30.11%	65 $12,000
Q3 2023 Oct 11, 2023	BUY	$179.87 - $225.13 $6,835 - $8,554	38 Added 69.09%	93 $17,000
Q2 2023 Aug 03, 2023	BUY	$178.3 - $266.78 $534 - $800	3 Added 5.77%	55 $10,000
Q1 2023 Apr 28, 2023	BUY	$215.53 - $274.5 $1,077 - $1,372	5 Added 10.64%	52 $11,000
Q4 2022 Feb 01, 2023	BUY	$125.51 - $229.3 $1,757 - $3,210	14 Added 42.42%	47 $10,000
Q3 2022 Oct 27, 2022	BUY	$131.8 - $202.24 $3,163 - $4,853	24 Added 266.67%	33 $4,000
Q2 2022 Jul 28, 2022	SELL	$121.11 - $216.05 $1,937 - $3,456	-16 Reduced 64.0%	9 $1,000
Q1 2022 Apr 21, 2022	BUY	$146.52 - $269.56 $1,758 - $3,234	12 Added 92.31%	25 $5,000
Q1 2021 Sep 15, 2021	SELL	$260.64 - $382.12 $1,824 - $2,674	-7 Reduced 35.0%	13 $4,000
Q1 2021 Apr 27, 2021	BUY	$260.64 - $382.12 $1,824 - $2,674	7 Added 53.85%	20 $7,000
Q4 2020 Sep 15, 2021	BUY	$221.31 - $316.61 $2,877 - $4,115	13 New	13 $4,000
Q4 2020 Jan 27, 2021	SELL	$221.31 - $316.61 $2,877 - $4,115	-13 Closed	0 $0
Q3 2020 Sep 15, 2021	BUY	$189.18 - $286.44 $2,459 - $3,723	13 New	13 $4,000
Q3 2020 Oct 19, 2020	SELL	$189.18 - $286.44 $2,459 - $3,723	-13 Closed	0 $0
Q2 2020 Sep 15, 2021	BUY	$123.9 - $195.41 $1,610 - $2,540	13 New	13 $4,000
Q2 2020 Jul 22, 2020	SELL	$123.9 - $195.41 $1,610 - $2,540	-13 Closed	0 $0
Q1 2020 Sep 15, 2021	BUY	$121.84 - $173.19 $1,583 - $2,251	13 New	13 $4,000
Q1 2020 Apr 28, 2020	SELL	$121.84 - $173.19 $1,583 - $2,251	-13 Closed	0 $0
Q4 2019 Sep 14, 2021	SELL	$115.78 - $208.34 $578 - $1,041	-5 Reduced 27.78%	13 $4,000
Q4 2019 Jan 27, 2020	BUY	$115.78 - $208.34 $578 - $1,041	5 Added 38.46%	18 $3,000
Q3 2019 Sep 14, 2021	BUY	$120.61 - $148.29 $1,567 - $1,927	13 New	13 $4,000
Q3 2019 Oct 22, 2019	SELL	$120.61 - $148.29 $1,567 - $1,927	-13 Closed	0 $0
Q2 2019 Sep 14, 2021	BUY	$113.99 - $146.86 $1,481 - $1,909	13 New	13 $4,000
Q2 2019 Jul 31, 2019	SELL	$113.99 - $146.86 $1,481 - $1,909	-13 Closed	0 $0
Q1 2019 Sep 02, 2021	BUY	$122.82 - $151.83 $1,351 - $1,670	11 Added 550.0%	13 $0
Q1 2019 Apr 22, 2019	BUY	$122.82 - $151.83 $245 - $303	2 New	2 $0

Others Institutions Holding BGNE

# of Institutions

252

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account